Fennec Pharmaceuticals Inc.
FENCHealthcare|Biotechnology|US
$9.81
+0.42 (+4.47%)
Tangible Book / Share
$1.23
Cash / Share
$1.19
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07407582 Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) | Solid Tumor Malignancies, Testicular Cancer | P1P2 | Recruiting | 25 | Open-label | Pedmark® STS |
| NCT04132882 A Compassionate Use Program to Provide Access to Sodium Thiosulfate | Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma | AVAILABLE | — | — | Sodium Thiosulfate (STS) |